Business
Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit
BOSTON, October 15, 2025--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that Goldman Sachs (NYSE:GS) is recognizing David H. Donabedian, Ph.D., Newleos’ Founding Chief Executive Officer and Executive Partner at Longwood Fund, as one of the Most Exceptional Entrepreneurs of 2025 at its Builders and Innovators Summit in Healdsburg, California.
About this update from Biogen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":850,"height":350,"url":"https://media.zenfs.com/en/business-wire.com/a555a0bfa6459bd96475d376c650c57b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1C5DevzsQyF7mWVJggtCyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a555a0bfa6459bd96475d376c650c57b","width":850,"height":350},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/KFoiQoV50eO7dQSuIAubRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE3MDA7aD03MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a555a0bfa6459bd96475d376c650c57b","width":850,"height":350}},"lazy":false},{"type":"text","content":"BOSTON, October 15, 2025--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that Goldman Sachs (NYSE:GS) is recognizing David H. Donabedian, Ph.D., Newleos’ Founding Chief Executive Officer and Executive Partner at Longwood Fund, as one of the Most Exceptional Entrepreneurs of 2025 at its Builders and Innovators Summit in Healdsburg, California.","length":462,"tagName":"p"},{"type":"text","content":"Goldman Sachs selected Dr. Donabedian from a diverse group of entrepreneurs across multiple industries to be honored at this two-day event for his proven record of founding, scaling, and successfully operating groundbreaking biotechnology companies. Prior to Newleos, he co-founded and led Axial Therapeutics, DEM BioPharma, and Solu Therapeutics in partnership with the Longwood Fund and currently serves as Co-Founder and as a member of the board of directors of Alcyone Therapeutics, which announced its acquisition by Biogen in September 2025. A former managing director of a corporate venture fund valued in excess of $100 million, Dr. Donabedian’s deep investment expertise is complemented by a track record of advancing transformative medicines across multiple disease indications and modalities to meet the needs of patients. Since its launch, Newleos has in-licensed a portfolio of first- and best-in-class clinical programs from Roche and advanced multiple assets into Phase 1b and Phase 2 clinical trials in under one year. The company has raised more than $93 million from a leading syndicate of in...